Research programme: bone disorders and inflammatory disease therapeutics - Galapagos

Drug Profile

Research programme: bone disorders and inflammatory disease therapeutics - Galapagos

Alternative Names: Bone and joint disorder therapeutics - Galapagos; GT146; GT328; GT442; Oral psoriasis therapy - Galapagos NV; Osteoporosis therapies - Galapagos; Rheumatoid arthritis therapies - Galapagos

Latest Information Update: 28 Aug 2013

Price : $50

At a glance

  • Originator ProSkelia
  • Developer Galapagos NV; Ghent University; Janssen Pharmaceutica; Pfizer
  • Class Antibodies; Small molecules
  • Mechanism of Action Integrin inhibitors; Osteogenesis stimulants; Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone disorders; Inflammation; Osteoporosis; Rheumatoid arthritis
  • Research Psoriasis

Most Recent Events

  • 08 Jul 2013 Early research in Psoriasis in Belgium (PO)
  • 03 Jul 2013 Preclinical development is ongoing in Belgium
  • 03 Apr 2013 Galapagos terminates collaboration with Eli Lilly for the development of osteoporosis therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top